Karo Bio AB and Wyeth Extend Research Collaboration

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: The Swedish company Karo Bio, listed on the Stockholm Stock Exchange (STO:KARO), today announced that Wyeth (NYSE:WYE) and Karo Bio extended their atherosclerosis collaboration for an additional year until August 31, 2008. The primary objective of the extension is to characterize back up compounds and to further evaluate additional clinical possibilities by targeting LXR.